1. Introduction {#sec1}
===============

Multiple sclerosis (MS) is an autoimmune disease characterized by the formation of inflammatory demyelinating lesions in the central nervous system. Although MS is normally diagnosed in adults, some patients experience clinical onset before the age of 18 ([@bb004]).

Focal MS lesions vary in their degree of myelin loss. Histopathological analysis of remyelination in the brain of MS patients is limited, and most specimens have been obtained from older adults with long-standing and often secondary progressive MS. Fully demyelinated lesions are common in these patients ([@bb0028]), but partially remyelinated "shadow plaques" are also observed ([@bb0030]), indicating that the adult brain has some ability to repair myelin. It has been suggested that remyelination capacity decreases with age ([@bb0016]; [@bb0018]) in humans and in animal models of induced CNS demyelination ([@bb0022]; [@bb0037]; [@bb0040]; [@bb0041]).

If remyelination capacity decreases with age in adults, we would expect children and adolescents with MS to have an even greater capacity for remyelination, and some clinical features of pediatric-onset MS suggest that this may be true. Children and adolescents usually recover completely from their first attack ([@bb008]; [@bb0038]) and rarely accrue physical disability within the first 10 years of the disease ([@bb0036]).

In order to investigate myelination as a function of age, as well as lesional remyelination capacity *in vivo*, an imaging technique sensitive to changes in myelin content is needed. Suitable methods include myelin water fraction (MWF), derived from multicomponent T2 mapping; restricted proton pool size, derived from quantitative magnetization transfer (qMT) imaging; and magnetization transfer ratio (MTR), which is a semi-quantitative measurement of magnetization exchange between free and bound proton pools. We have used an MTR-based approach in this study because data with the required resolution for lesion-based analyses can be acquired relatively quickly, an important issue for pediatric studies. MTR has been histopathologically validated as a marker for myelin in both humans and animals and has excellent quantitative correlation with the Luxol fast blue stain, which is attracted to lipoproteins in the myelin sheath and is used as a standard stain for myelin ([@bb005]; [@bb0012]; [@bb0014]; [@bb0015]; [@bb0032]; [@bb0039]).

Changes in MTR over time in new lesions exhibit a typical pattern of sudden decrease at the time of lesion formation, followed by partial recovery. We have developed an MTR imaging-based technique that uses longitudinal scanning to identify focal areas of tissue that experience an acute decrease in MTR (corresponding to demyelination) and quantify subsequent recovery (remyelination) ([@bb0010]). These "ΔMTR" lesions are distinct from other lesion types normally identified in MS, such as hyperintensities on T2-weighted or gadolinium contrast enhanced scans; because they are identified on MTR images, they are more specific to demyelination ([@bb0010]). The MTR timecourse within these lesions can be modeled and produces a statistically powerful measurement of differences in MTR recovery, indicative of remyelination.

If the capacity for repair of MS lesions is particularly robust when concurrent with ongoing myelin maturation or other developmental factors, we would expect that adolescent MS patients would have a greater capacity to repair lesions in early adolescence than in late adolescence/early adulthood, as primary myelination reaches completion.

We quantify changes in lesional MTR in a cohort of adolescents with MS imaged longitudinally from mid-adolescence to early adulthood. We hypothesize that MS lesion remyelination capacity, measured by MTR recovery, (1) decreases rapidly with age in adolescents with MS, and (2) in older adolescents, reaches a level comparable to that seen in adults with MS.

2. Material and methods {#sec2}
=======================

2.1. Subjects {#sec2.1}
-------------

All subjects were selected from a single site (The Hospital for Sick Children, Toronto), and all were imaged on the same 1.5 T MRI scanner. Subjects were selected from two studies: our national study of acquired demyelination in Canadian children ([@bb003]),and from a serial MRI and neurocognitive study of pediatric MS ([@bb0042]). Subjects selected from the national Canadian study were imaged from the first attack, at 3, 6 and 12 months, and annually. Subjects enrolled in the MRI and neurocognitive study were enrolled at variable timepoints post-MS onset and were imaged two to four times, 12 months apart.

For selection for the present analysis, subjects were required (1) to have a diagnosis of relapsing--remitting MS according to the McDonald 2005 criteria ([@bb0033]) --- the 2010 McDonald criteria were not available at the time of diagnosis for many of the patients; (2) to have serial scans with high quality MTR imaging, and for these scans to include at least one scan prior to detection of a new lesion, one scan with a new lesion, and one scan at least 6 months after the scan with the new lesion; (3) to be between 15 and 21 years of age at the time of the MRI scan with new lesions; (4) to have their new lesion scan at least 6 months after their incident attack; (5) to have all scans selected to be more than 30 days from a clinical relapse or any corticosteroid exposure; and (6) to either be free of any immunomodulatory therapy or treated with one of the current disease-modifying therapies (DMTs): glatiramer acetate (GA; Copaxone, Teva Pharmaceutical Industries, Petah Tiqva, Israel), or one of two formulations of interferon β-1a (IFN-R; subcutaneous Rebif, Merck Serono International, Geneva, Switzerland or IFN-A; intramuscular Avonex, Biogen, Cambridge, USA). No patient was treated with interferon-beta 1b so we did not include this in our criteria. Very few pediatric MS patients were exposed to other therapies, such as natalizumab or cyclophosphamide, and any such patients were excluded.

2.2. Imaging {#sec2.2}
------------

Images were acquired on a single 1.5 T GE TwinSpeed Excite 12.0 scanner (GE Medical Systems, Milwaukee, USA). Sequences obtained included: T1-weighted (T1; sagittal SPGR, T~R~ = 22 ms, T~E~ = 8 ms, 1.5 × 1 × 1 mm, flip angle 30°), T2-weighted and proton density-weighted (T2, PD; dual echo axial FSE, T~R~ = 3500 ms, T~E~ = 15, 63 ms, 1 × 1 × 2 mm), and magnetization transfer images (axial SPGR, T~R~ = 27 ms, T~E~ = 4 ms, 1.5 × 1.5 × 1.5 mm, flip angle 12°) with (MT~ON~) and without (MT~OFF~) a magnetization transfer pulse (8 ms Fermi). Voxel sizes are all right/left × anterior/posterior × superior/inferior. An adult male volunteer was also scanned at intervals on the same scanner with the same protocol as a "living phantom." MTR images were calculated for each subject at each timepoint using the formula $\mathit{MTR} = 100 \cdot \frac{MT_{\mathit{OFF}} - MT_{\mathit{ON}}}{MT_{\mathit{OFF}}}$ and normalized using the living phantom data, according to the procedure in [@bb0010]. This normalization process maps raw MTR measurements onto a calibrated scale, where normal white matter (WM), as defined by the living phantom, has a value of 1 and normal gray matter (GM) has a value of 0, and reduces inter-scanner variability to below the level of inter-subject variability ([@bb0011]), as well as corrects potential longitudinal changes in measured MTR on a single scanner. Although MTR measurements are unitless, we will refer to measurements on this scale as being in normalized MTR units (nMU) for clarity.

2.3. Preprocessing {#sec2.3}
------------------

All images for each subject were co-registered (minctracc, McConnell Brain Imaging Centre, Montreal, Quebec, Canada ([@bb0013])) and probability maps for WM, GM, cerebrospinal fluid (CSF) and T2 lesions were constructed using a Bayesian classifier with the T1, T2 and PD images as input ([@bb0017]). T2 lesion masks were automatically generated from the T2 lesion probability maps, reviewed and, if necessary, edited by trained readers. Longitudinally-consistent high confidence WM and GM masks (HCWM, HCGM) were constructed, consisting of tissue identified as having greater than 85% probability WM or GM at every timepoint. Finally, *de novo* ΔMTR lesion masks were generated as previously described ([@bb0010]). ΔMTR lesions were segmented from MTR difference images by identifying focal areas of newly-appearing MTR signal decrease. *De novo* ΔMTR lesions were defined as those occurring in previously normal-appearing WM.

2.4. Analysis {#sec2.4}
-------------

Each lesion was assigned a unique identifier and regions of interest (ROIs) corresponding to each lesion were identified on all scans. MTR values of voxels within the ROI were averaged, producing a mean lesion MTR measurement at each timepoint. Together with the elapsed time relative to the lesion appearance, these data form an MTR timecourse for the lesion, showing MTR evolution from before lesion formation, through acute inflammation, to post-lesion follow-up. From other data ([@bb0010]) we have observed that MTR values in lesions change rapidly during the acute inflammatory phase, decreasing from about 1 month before the lesion is observed, recovering partially by 3 months, and then remaining relatively stable in the longer term ([@bb0010]). MTR measurements made during the period of acute lesion formation could be influenced by inflammation and its resolution. For these reasons, only samples acquired outside the acute period (defined as 1 month prior to 3 months after lesion formation) were included in our statistical models, although all data have been graphed to illustrate the entire timecourse.

The primary goal of the analysis was to detect changes in the amount of MTR recovery with age. However, disease duration and treatment status might be significant confounding factors. Since disease duration and age are correlated longitudinally, these should not both be factors in the same model. Therefore, we used age at onset in place of disease duration, which corrects for any effects related to disease duration, independent of the age at which a new lesion is observed.

MTR timecourses were modeled using a general linear mixed model (GLMM) in R ([@bb0034]) using the lme4 package ([@bb006]) with the formula: $$\begin{array}{l}
{\left. \mathit{MTR} \right.\sim\mathit{age} + \mathit{ageAtOnset} + \mathit{treatment} + \mathit{recovery} + \mathit{recovery}:\mathit{age} + \mathit{recovery}:\mathit{ag}e^{2}} \\
{\quad + \mathit{recovery}:\mathit{treatment} + \mathit{recovery}:\mathit{ageAtOnset} + \left( 1\left| \mathit{subject}/\mathit{timepoint} \right)/\mathit{lesion} \right)} \\
\end{array}$$

where ":" indicates an interaction and (1\|subject/timepoint/lesion) is a nested random intercept. The subject\'s age at new lesion formation, age at onset, and treatment at the time of lesion appearance, plus a dummy variable *recovery* indicating that the MTR measurement was taken after the lesion formed, were the main fixed effects; interactions of recovery with each of age at lesion appearance, treatment, and age at onset were included. As we expected the remyelinative capacity to decrease rapidly in adolescence and then stabilize as subjects approached adulthood, we also included an interaction between *age*^2^ and *recovery*, allowing the rate of change to accelerate or decelerate with age. The random effects were lesion, nested within timepoint, within subject. This random effects structure accounts for correlations between lesions within a subject, lesions appearing at the same timepoint, and between measurements taken over time in each lesion. The *recovery* factor measures the change in MTR from a stable pre-lesion value to stable post-lesion value. We expect the recovery to be negative, indicating that the MTR recovers only partially. The *recovery*:*age* and *recovery*:*age*^2^ interactions measure changes in the amount of recovery demonstrated by lesions that appear in subjects at different ages. Since measurements taken from larger lesions are averaged over more voxels, these measurements have a lower variance as well as being less affected by partial volume effect. The standard error decreases by the square root of the number of averaged samples, so measurements were weighted in the model by the square root of the volume of the lesion they were taken from.

Age at lesion appearance and age at onset values were "centered" by subtracting 16 and 13, respectively, so the modeled effects are relative to a 16 year old subject with an age of onset of 13 years. Centering variables that have a non-zero mean, such as age, is a recommended modeling practice. In this case it makes explicit that a linear trend is not being imposed from birth, making interpretation of the results more straightforward. The fit of the model as a whole was evaluated by comparing the log-likelihoods of the model and a null model using a χ^2^ test. If this "gateway test" was significant, individual effects were evaluated using *f*-tests, with denominator degrees of freedom estimated using a Satterthwaite approximation, by the R package MixMod ([@bb0024]). This methodology eliminates the need for multiple comparisons when examining orthogonal contrasts within the model. *R*^2^ values were produced according to the procedure suggested by [@bb0029], where the marginal *R*^2^ is the variance explained by the fixed effects alone, and the conditional *R*^2^ is the variance explained by the entire model including random effects.

Measurements of the post-lesion MTR value have less statistical power to detect changes in recovery than the pre- to post-lesion difference ([@bb0010]), but may be useful for comparisons when the pre-lesion MTR values are very different, such as when comparing subjects with short disease duration with those who have long-standing diffuse white matter changes. These values were calculated by summing the relevant factors from the model.

3. Results {#sec3}
==========

The final dataset included data from 241 new lesions in 19 pediatric-onset MS patients (2 males, 17 females). Lesions were identified on 26 unique scans, thus several subjects had new lesions at more than one timepoint ([Fig. 1](#f0005){ref-type="fig"}). Subjects were aged 15.6--20.1 years (mean 17.4, median 17.1) at the time of lesion appearance and age at first attack ranged from 5.3 to 16.7 years (mean 12.5, median 13.2). Treatments at the time of lesion appearance were IFN-R: 5; IFN-A: 6; GA: 12 and no DMT: 3. Demographic data are summarized in [Table 1](#t0005){ref-type="table"}.

As illustrated in [Fig. 2](#f0010){ref-type="fig"}, an acute decrease in MTR at the time of lesion formation was noted, followed by partial recovery. [Table 2](#t0010){ref-type="table"} provides the results of the model fit. The model fit is significantly better than the null model (*p* \< 0.0001) and achieved a marginal *R*^2^ of 0.54 and a conditional *R*^2^ of 0.81. Pre-lesion MTR values had a mean of 1.10 nMU and did not change significantly with age at scan (*p* = 0.99). New MTR lesions exhibited a significant reduction of MTR signal to a post-lesion level of 0.65 nMU (*p* \< 0.0001) in the reference case (age = 16, age at onset = 13, no DMT). Older age at onset was associated with slightly poorer recovery (−0.015 nMU/year; *p* = 0.0004). MTR signal recovery within lesions decreased significantly with increasing age at lesion appearance (−0.19 nMU/year, *p* = 0.023). The quadratic term age^2^ was positive, but not significant (0.032 nMU/year^2^; *p* = 0.39). Treatment with DMTs was also a significant factor in recovery (*p* = 0.0003).

Since the recovery--age relationship is of primary interest and quadratic terms can have large effects on model fits, the model was refit without the age^2^ factor, yielding similar results and no change in the statistical significance of any factors. To determine whether our results were impacted by a small number of subjects with a large number of lesions, we fit the model using subject-wise data where values from lesions within individual subjects were averaged. Although *p*-values in the resulting model were increased due to the effective reduction in sample size, the model yielded similar results, with no change in significance except for the *recovery:age at onset* factor (*p* = 0.34).

[Fig. 3](#f0015){ref-type="fig"} shows the pre- to post-lesion MTR difference (*recovery*) as a function of age at lesion appearance. The round markers indicate measurements in individual lesions. Some subjects had recovery measurements from lesions at more than one timepoint, and these are indicated by light lines joining the volume-weighted mean recovery value at each timepoint. Vertical lines connect measurements from multiple new lesions at the same timepoint in individual subjects. A predicted mean curve from the model is shown as a heavy line with shading indicating the 95% confidence region.

The *Prediction* column of [Table 2](#t0010){ref-type="table"} gives predicted MTR values for the reference case: the predicted post-lesion MTR value for untreated 16 year olds (onset at age 13) was 0.45 nMU while for eighteen year olds it was 0.13.

4. Discussion {#sec4}
=============

We demonstrated an age-related decline in lesional recovery during adolescence and into early adulthood. The onset of MS during childhood and adolescence is associated with limited accrual of physical disability in the first 10 years of disease ([@bb008]; [@bb009]; [@bb0036; @bb0035]; [@bb0043]). Although there may exist several explanations for the preservation of physical function seen in pediatric MS patients, one possible mechanism could be effective repair of lesions. We and others have shown that the overall lesion burden, as measured by both T2- and T1-weighted images, is similar in pediatric- and adult-onset MS ([@bb0019; @bb0020]; [@bb0044]). Thus, the lower risk of physical disability cannot be attributed to a lower lesion burden in children and adolescents. We have also recently shown that pediatric-onset MS patients have lower global and regional brain volumes, compared to healthy age- and sex-matched pediatric populations ([@bb002]; [@bb0023]), further indicating that pediatric-onset MS patients are not spared from the injurious pathology that characterizes MS. Thus, preserved physical functioning in the face of active inflammatory disease may relate to improved remyelination within lesions or potentially to a heightened capacity of pediatric patients to marshal alternative neural networks (plasticity).

Although we did not have an adult control group acquired on the same scanner with the same protocol with which to compare, published data in adults ([@bb0010]) offers a qualitative comparator. We previously report pre-lesion MTR values in adults of about 0.5 nMU, which compares to 1.1 nMU in adolescents in this study; normal adult WM has a median value of 1.0 nMU. Children and young adolescents are expected to have slightly higher WM MTR than normal adults because MTR has been observed to decrease slightly, at least in males, during adolescence ([@bb0031]). The very low pre-lesion value observed in adults with MS suggests that these patients have accumulated considerable diffuse WM damage.

Post-lesion MTR values in *de novo* ΔMTR lesions in adults were approximately 0 nMU ([@bb0010]), compared to 0.45 nMU and 0.13 nMU in sixteen and eighteen year olds, respectively. These values indicate that early adolescents enjoy a heightened capacity for remyelination compared to late adolescence and adulthood. Adult patients between 18 and 20 years of age were already demonstrating post-lesion MTR values comparable to those seen in older adults. This observation, as well as the positive *age*^2^ effect estimated by our model, is consistent with the hypothesis that young adolescents enjoy a heightened capacity for remyelination, which is lost as they enter adulthood.

Reduced remyelinative capacity in late adolescence could be caused by the loss of factors uniquely associated with brain development, which are lost at the end of adolescence, or by the same processes that produce slow decline in adults. Various studies, primarily in animals, have attempted to identify the causes of adult age-related decreases in remyelination. These have observed increasing delays in (1) colonization of lesions by oligodendrocyte precursor cells (OPCs) ([@bb0041]), (2) OPC differentiation ([@bb0041]), (3) upregulation of growth factor expression ([@bb0022]) and (4) macrophage response ([@bb0022]; [@bb0037]) with increasing age, as well as inefficient suppression of OPC differentiation inhibitors ([@bb0040]) and decreased efficiency of myelin debris clearance ([@bb0021]). Recently, Ruckh et al. used rats with surgically connected circulatory systems (parabiotically bound partners) to demonstrate that remyelination in older rats can be improved through the availability of peripheral macrophages provided by young partners ([@bb0037]).

Associations between adolescent brain development and myelination are suggested by the observation that white matter volume increases during adolescence and early adulthood ([@bb001]; [@bb0027]; [@bb0031]). This may be due to ongoing primary myelination, which might continue into early adulthood, at least in some brain regions ([@bb007]; [@bb0026; @bb0025]). There is also evidence that late adolescent growth in white matter may be at least partially due to increases in axon caliber ([@bb0031]), which may require active remodeling of the myelin sheath to accommodate thickening axons. These processes may be supported by an adolescent brain microenvironment that is also more favorable for robust remyelination.

The association we observed between older age at disease onset and *poorer* recovery is at first glance surprising: later onset implies shorter disease duration for a subject of a given age. Since disease duration is correlated with both age and age at onset, it can be difficult to separate the effects of these three factors, but it is possible that patients who develop MS at a younger age may experience delayed development, retaining remyelination-enhancing developmental factors to an older age.

We detected a significant decrease in MTR recovery in lesions in adolescent MS patients imaged from mid-adolescence to early adulthood. The heightened reparative capacity in the younger adolescents may, in part, explain the limited physical disability seen in these patients. Whether the relative loss of reparative capacity in early adulthood will render patients at the same risk of disability as adult-onset MS patients remains to be seen. Further studies of even younger MS patients will determine whether myelin repair is even greater in periods of more active primary myelination.
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Table A.1Parameter estimates of the subject-wise statistical model.EffectEstimate (nMU)Degrees of freedom*fp*Intercept1.18------Age−0.044/year1/220.970.33**Recovery−0.751/4824\<0.0001**Recovery:age at onset−0.0075/year1/660.910.34**Recovery:age−0.073/year1/484.10.049Recovery:treatment (IFN-A)0.233/623.60.018Recovery:treatment (IFN-R)0.037Recovery:treatment (GA)−0.041Random effects**SubjectVariance = 0.20ResidualVariance = 0.76[^1]
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![Histograms of lesion distribution by subject and age. The data exhibited the expected distribution of new lesion counts with most subjects having only a few while others had many. The number of new lesions was distributed approximately uniformly by age except for an increased number around the age of 16; many subjects started disease modifying therapy around this age.](gr1){#f0005}

![MTR timecourses in *de novo* ΔMTR lesions. Light lines indicate individual timecourses while heavy lines are estimates generated from a model. Shaded areas indicate 95% confidence regions. Lesions showed MTR decreasing at the time of lesion formation (time 0), then recovering partially afterward. The *recovery* value is the difference between the stable post-lesion value and the stable pre-lesion value. Sample curves from the model for an average 16 year old (solid) and a 19 year old (dashed), both with MS onset at age 13, are shown.](gr2){#f0010}

![The difference between post- and pre-lesion MTR by age. A recovery value of 0 indicates full post-lesion MTR recovery to baseline while negative values indicate partial recovery. Circles indicate measured values in individual lesions. Light lines connect mean values for subjects with new lesions and enough data to measure recovery at multiple timepoints. The dark line indicates the model prediction for the average subject and the shaded area is the 95% confidence region. MTR recovery decreases significantly with age.](gr3){#f0015}

###### 

Subject demographics.

  --------------------------------------------------------------------
                                          Minimum   Median   Maximum
  --------------------------------------- --------- -------- ---------
  Age\                                    15.6      17.1     20.1
  (years; at time of lesion appearance)                      

  Age at First Attack (years)             5.3       13.2     16.7

                                                             
  --------------------------------------------------------------------

  ---------------------------------------------------------
  Sex                              Male: 2     Female: 17
  -------------------------------- ----------- ------------
  Treatment\                       No DMT: 3   GA: 12
  (at time of lesion appearance)               

  IFN-A: 6                         IFN-R: 5    
  ---------------------------------------------------------

###### 

Parameter estimates of the statistical model.

  -------------------------------------------------------------------------------------------------------------------------------------------
  Effect                           Estimate (nMU)                   Prediction\                Degrees of freedom   *f*        *p*
                                                                    (nMU, reference subject)                                   
  -------------------------------- -------------------------------- -------------------------- -------------------- ---------- --------------
  Intercept                        1.10                             1.10                       --                   --         --

  Age                              −0.013/year                      1.10                       1/34                 0.00       0.99

  **Recovery**                     **−0.65**                        **0.45**                   **1/480**            **263**    **\<0.0001**

  **Recovery:age at onset**        **−0.015/year**                  **0.45**                   **1/431**            **12.8**   **0.0004**

  **Recovery:age**                 **−0.19/year**                   **0.45**                   **1/518**            **5.18**   **0.023**

  Recovery:age^2^                  0.032/year^2^                    0.45                       1/504                0.740      0.39

  **Recovery:treatment (IFN-A)**   **0.08**                         **0.53**                   **3/463**            **6.46**   **0.0003**

  **Recovery:treatment (IFN-R)**   **0.0067**                       **0.45**                                                   

  **Recovery:treatment (GA)**      **−0.23**                        **0.22**                                                   

  **Random effects**               **χ^2^ = 223; *p* \< 0.00001**                                                              

   Lesion                          Variance = 0.056                                                                            

   Timepoint                       Variance = 0.000                                                                            

   Subject                         Variance = 0.040                                                                            

   Residual                        Variance = 0.066                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------

p \> 0.05 using a standard general linear mixed model f-test with denominator degrees of freedom estimated by the Satterthwaite approximation, as discussed in the methods.

[^1]: p \< 0.05 on a standard general linear mixed model f-test using denominator degrees of freedom estimated by a Satterthwaite approximation, as discussed in the methods.
